AdvaMed 2014 will feature four Funding Forums addressing critical issues in financing and growth in the medical technology industry. Early-stage company executives and investors will benefit from these interactive discussions and gain insights into raising capital and forming strategic partnerships. Funding Forums at AdvaMed 2014 are co-located with Company Presentations and Sector MeetUps, providing a comprehensive business development program for early-stage companies, investors and corporate business development executives.
Early-Stage Funding Forum: The Angel, the Crowd and the Cause
Angel investment activity increased in 2013 and remains a vital source of early-stage capital for MedTech. At the same time, crowdfunding and philanthropic investments have emerged as viable options for funding health care innovations. With venture capital scarce, early-stage MedTech companies increasingly seek support from foundations that fund medical research. And with the advent of the JOBS act, individual investor pools are now accessible through crowdfunding platforms. This Forum will assess how the crowdfunding model applies to MedTech investing, and describe how entrepreneurs are working with foundations and angel investors to fund new MedTech businesses.
Corporate Business Development Forum
Strategic investments and M&A continue to be significant drivers of health care innovation. Corporate business development executives will discuss their approach to strategic investments and identify important elements of the due diligence process and key factors for successful deal making. This Forum will also include the perspective of a small company executive on developing partnerships and securing strategic investments.
Venture Capital Forum
Corporate venture investments are an increasingly important element of capital formation for MedTech companies, as uncertain regulatory and reimbursement conditions threaten already scarce venture capital. Venture capital funding for medical devices declined 17 percent (in dollars) in 2013 and accounted for only seven percent of all venture capital funding in the U.S. This Forum will discuss trends and new models in venture capital funding and provide guidance for early stage companies on presenting a comprehensive value proposition to both corporate investors and traditional VCs.
Growth-Stage Funding Forum: Outlook for IPO and M&A Activity
While M&A is often the most likely exit strategy for growth-stage MedTech companies, the public markets have recently shown signs of opening to MedTech IPOs. This Forum will examine the impact on MedTech IPOs of reduced reporting requirements for qualifying emerging growth Companies, and address the steps growth-stage MedTech companies can take to manage the costs and complexity of an IPO. Against this backdrop, the panel will also assess the current landscape for M&A and the corporate business development perspective on deal making with publicly listed and privately held MedTech companies.